Clinical trials: Claudication, Intermittent
Intermittent Claudication
BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers
The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of…
- Trial name
- NCT06167265
- Testing
- Cilostazol Tablet 100 mg, PMR Tablet 145 mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Spinal Stenosis, Lumbar Region, With Neurogenic Claudication
The MiDAS ENCORE Study
Study Objective: To compare patient outcomes following treatment with either the MILD procedure or epidural steroid injections (ESIs) in patients with painful lumbar spinal stenosis exhibiting neurogenic claudication and having…
- Trial name
- NCT02093520
- Testing
- MILD Procedure, Epidural Steroid Injection
- Where
- 12 sites in United States
- Volunteers
- 302 people
- Sponsor
- Vertos Medical, Inc.
Intermittent Claudication
Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication
The study is designed to compare the efficacy and safety of once daily PMR treatment with twice daily Pletaal® treatment in patients with intermittent claudication caused by peripheral arterial disease and are currently treated…
- Trial name
- NCT06886620
- Testing
- Cilostazol 200 mg, Cilostazol 100 mg
- Where
- 5 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Intermittent Claudication
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
- Trial name
- NCT00403494
- Testing
- Sapropterin Dihydrochloride
- Where
- 20 sites in United States, Argentina
- Volunteers
- 190 people
- Sponsor
- BioMarin Pharmaceutical
Intermittent Claudication
BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of…
- Trial name
- NCT05466734
- Testing
- Cilostazol Tablet 100 mg, PMR Tablet 135 mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Stage II Peripheral Arterial Occlusive Disease, Intermittent Claudication Fontaine Stage II PAOD
Prostaglandin E1 in Outpatients With Intermittent Claudication
Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with…
- Trial name
- NCT01263925
- Testing
- Alprostadil (Prostaglandin E1), Pentoxifylline
- Where
- 36 sites in Germany
- Volunteers
- 561 people
- Sponsor
- UCB Pharma
Intermittent Claudication
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
Peripheral arterial disease (PAD) is almost invariably associated with a generalized atherosclerotic involvement of the arterial tree and endothelial dysfunction.
- Trial name
- NCT01256775
- Testing
- NCX-4016
- Where
- Italy
- Volunteers
- 442 people
- Sponsor
- NicOx Research Institute S.r.l.
Intermittent Claudication
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
The primary objective is to investigate in patients suffering from intermittent claudication due to Fontaine stage II Peripheral Arterial Disease (PAD) whether a 26-week treatment by HMR1766 on top of clopidogrel may result in an…
- Trial name
- ACCELA (NCT00443287)
- Testing
- ataciguat (HMR1766), cilostazol
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 553 people
- Sponsor
- Sanofi
Intermittent Claudication, Peripheral Vascular Disease
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
The purpose of this study is to compare the dose response and safety of Niacin ER/Lovastatin, Niaspan® and Lovastatin with each other, in subjects with leg pain caused by a narrowing of their leg arteries.
- Trial name
- NCT00071266
- Testing
- Niacin Extended Release and Lovastatin Tablets
- Where
- 26 sites in United States
- Volunteers
- 870 people
- Sponsor
- Kos Pharmaceuticals
Critical Limb Ischemia
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
The purpose of this study is to evaluate whether intramuscular injections of VM202 into the calf is safe and effective in the treatment of critical limb ischemia.
- Trial name
- NCT01064440
- Testing
- Low Dose VM202, High Dose VM202
- Where
- 16 sites in United States, South Korea
- Volunteers
- 52 people
- Sponsor
- Helixmith Co., Ltd.
Intermittent Claudication, Peripheral Artery Disease
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with peripheral artery disease and…
- Trial name
- NCT01131013
- Testing
- 375 mg CK-2017357, 500 mg CK-2017357
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- Cytokinetics
Intermittent Claudication
Mixed Antagonist of Serotonin for Claudication Optimal Therapy
To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity, by comparing…
- Trial name
- MASCOT (NCT00300339)
- Testing
- SL650472, Clopidogrel
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 599 people
- Sponsor
- Sanofi
Peripheral Arterial Disease
Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II
The purpose of this study is to evaluate the safety and efficacy of new intermittent pneumatic compression device on initial claudication distance in patients with Peripheral Arterial Disease stage II
- Trial name
- NCT00762086
- Testing
- AngioPress Intermittent pneumatic compression (IPC) Device, Medications and Standard walking exercises
- Where
- 4 sites in Germany, Israel
- Volunteers
- 67 people
- Sponsor
- Mego Afek Ltd.
Intermittent Claudication
A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions
The primary objective of this trial is to test whether Pletal ODT administered without water can be considered bioequivalent to Pletal administered with 200 ml water (both treatments being administered after fasting and at least…
- Trial name
- NCT00773630
- Testing
- Cilostazol
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Otsuka Frankfurt Research Institute GmbH
Peripheral Vascular Diseases, Intermittent Claudication
Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)
Patients with peripheral artery disease have decreased blood flow to exercising muscle causing pain. This decreased blood flow to the muscle affects the level of acylcarnitines which in turn decreases the level of carnitine.
- Trial name
- NCT00399919
- Testing
- Propionyl-L-Carnitine, PLC
- Where
- 9 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sigma-Tau Research, Inc.
Peripheral Arterial Disease
ILLUMENATE Below-The-Knee (BTK) Arteries: a Post Market Clinical Study
The objective of this prospective, multi-center, single arm study is to obtain further data on the safety and performance of the StellarexTM 0.014" OTW Drug-coated Angioplasty Balloon in the treatment of lesions in "below the…
- Trial name
- BTK PMS (NCT03395236)
- Testing
- StellarexTM 0.014" Over-The-Wire Drug-coated Angioplasty Balloon
- Where
- 10 sites in Germany, Netherlands and 1 more
- Volunteers
- 49 people
- Sponsor
- Spectranetics Corporation
Peripheral Artery Disease, Claudication
Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries
The primary objective of this study is to prove the superior performance of the Ranger™ paclitaxel-coated PTA balloon catheter for angioplasty for femoropopliteal artery lesions when compared to non-coated balloons at six months…
- Conditions
- Peripheral Artery Disease, Claudication, Atherosclerosis, Arteriosclerosis
- Trial name
- RANGER-SFA (NCT02013193)
- Testing
- Ranger DCB, uncoated PTA balloon
- Where
- 11 sites in Austria, France and 1 more
- Volunteers
- 105 people
- Sponsor
- Hemoteq AG
Neurologic Claudication in Patients With Lumbar Spinal Stenosis
A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis
This trial is a comparative study of Opast tablet and Rikalin capsule 75mg and Rikalin capsule 75mg in combination with Opast tablet to evaluate improvement effectiveness of Opast tablet on subjective symptoms and neurologic…
- Trial name
- NCT01888536
- Testing
- Limaprost, Pregabalin
- Where
- 7 sites in South Korea
- Volunteers
- 182 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
Intermittent Claudication
Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers
The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of…
- Trial name
- NCT05191862
- Testing
- Cilostazol 100 mg, PMR 135 mg
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Iliac Artery Stenosis
EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries
The ORION study is being conducted to determine whether the Epic™ Nitinol Stent for primary stenting of iliac atherosclerotic lesions shows acceptable performance at 9 months.
- Trial name
- ORION (NCT00896337)
- Testing
- Epic™ Nitinol Stent System, Anti-platelet therapy, Anti-coagulation therapy
- Where
- 28 sites in United States
- Volunteers
- 125 people
- Sponsor
- Boston Scientific Corporation